Departments of Neurosurgery, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey.
J Neurosurg Spine. 2012 Jan;16(1):57-60. doi: 10.3171/2011.9.SPINE11401. Epub 2011 Oct 21.
Imatinib mesylate has become the treatment of choice for gastrointestinal stromal tumors (GISTs) and has made a revolutionary impact on survival rates. Bone marrow necrosis is a very rare adverse event in malignant GIST. Bone metastases are also rarely encountered in the setting of this disease. The authors report on a patient with malignant GIST who developed a bone lesion, mimicking spinal metastasis on both MR imaging and FDG-PET/CT. Corpectomy and anterior fusion was performed, but the pathology report was consistent with bone marrow necrosis. Radiological and clinical similarities made the distinction between metastasis and bone marrow necrosis challenging for the treating physicians. Instead of radical surgical excision, more conservative methods such as percutaneous or endoscopic bone biopsies may be more useful for pathological confirmation, even though investigations such as MR imaging and FDG-PET/CT indicate metastatic disease.
甲磺酸伊马替尼已成为胃肠道间质肿瘤(GIST)的治疗选择,对生存率产生了革命性的影响。骨髓坏死是恶性 GIST 非常罕见的不良反应。在这种疾病中,骨转移也很少见。作者报告了一例恶性 GIST 患者,该患者出现了骨病变,在 MRI 和 FDG-PET/CT 上均类似于脊柱转移。进行了椎体切除术和前路融合术,但病理报告与骨髓坏死一致。放射学和临床相似性使得治疗医生难以区分转移和骨髓坏死。对于治疗医生来说,与激进的手术切除相比,经皮或内镜骨活检等更保守的方法可能更有助于病理证实,即使 MRI 和 FDG-PET/CT 等检查表明存在转移性疾病。